Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: observational diagnostic model development.
- Who it may be relevant to
- Registry conditions: Deep Learning, Ultrasound, Bladder Cancer. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound
Overview
This study aims to develop an ultrasound image-based deep learning system to enable automatic segmentation, T-staging, and pathological grading prediction of bladder tumors. It seeks to enhance the objectivity, accuracy, and efficiency of bladder cancer diagnosis, reduce reliance on physician experience, and provide support for precision medicine and resource optimization.
Interventions
- Other observational diagnostic model development
observational diagnostic model development
Primary outcome measures
- Overall Diagnostic Accuracy [Time frame: From may 2025 to may 2027]
Eligibility criteria
Inclusion Criteria:① Suspected bladder mass detected by abdominal ultrasound (age ≥18 years);② Patients scheduled for surgical treatment of bladder tumors.
Exclusion criteria
- Age >85 years;
- Patients unable to undergo abdominal/transrectal ultrasound (e.g., uncooperative individuals, technically inadequate images);
- History of bladder tumor surgery, radiotherapy, chemotherapy, or systemic therapy within 3 months; ④ Patients with indwelling medical devices (e.g., double-J ureteral stents, urinary catheters);
- Failure to undergo bladder tumor surgery within 2 weeks post-ultrasound; ⑥ Non-urothelial carcinoma or pathologically unconfirmed diagnoses.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Department of Urology, Peking University First Hospital — Beijing
Identifiers
NCT: NCT07111364 · BCA-AI-US